Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.
Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.
复制标题
β-受体阻滞剂可降低慢性阻塞性肺病患者的死亡和病情加重风险：观察性研究的荟萃分析
DOI：
10.1371/journal.pone.0113048
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Chen Y
中科院分区：
文献类型：
--
作者：
Du Q;Sun Y;Ding N;Lu L;Chen Y
背景心血管疾病是慢性阻塞性肺疾病（COPD）患者死亡的主要原因。β受体阻滞剂已被证明可以降低心脏病患者的发病率并提高其生存率。但是β受体阻滞剂对COPD患者预后的影响仍存在争议。本荟萃分析的目的是评估β受体阻滞剂对COPD患者死亡率和急性加重的影响。方法应用计算机检索EMBASE、MEDLINE和科克伦量表，检索β受体阻滞剂治疗COPD的相关研究。采用随机效应模型荟萃分析评价对COPD总死亡率和急性加重的影响。结果纳入15个原始观察性队列研究，随访时间为1 ~ 7.2年。结果显示，β受体阻滞剂治疗显著降低了COPD总体死亡率和加重的风险。总死亡率的相对危险度（RR）为0.72（0.63 - 0.83），COPD加重的相对危险度（RR）为0.63（0.57 - 0.71）。在COPD合并冠心病或心力衰竭患者的亚组分析中，总死亡率的风险分别为0.64（0.54-0.76）和0.74（0.58-0.93）。结论COPD患者应用β受体阻滞剂不仅可以降低总死亡率，而且可以降低COPD加重的风险。COPD患者心血管疾病的β受体阻滞剂处方需要改进。
Background Cardiovascular disease is a primary cause of death in patients with chronic obstructive pulmonary disease (COPD). Beta-blockers have been proved to reduce morbidity and improve survival in patients with cardiac diseases. But the effects of beta-blockers on outcomes in patients with COPD remain controversial. The objective of this meta-analysis was to assess the effect of beta-blockers on mortality and exacerbation in patients with COPD. Methods An extensive search of the EMBASE, MEDLINE and Cochrane was performed to retrieve the studies of beta-blockers treatment in patients with COPD. The random effects model meta-analysis was used to evaluate effect on overall mortality and exacerbation of COPD. Results Fifteen original observational cohort studies with a follow-up time from 1 to 7.2 years were included. The results revealed that beta-blockers treatment significantly decreased the risk of overall mortality and exacerbation of COPD. The relative risk (RR) for overall mortality was 0.72 (0.63 to 0.83), and for exacerbation of COPD was 0.63 (0.57 to 0.71). In subgroup analysis of COPD patients with coronary heart disease or heart failure, the risk for overall mortality was 0.64 (0.54–0.76) and 0.74 (0.58–0.93), respectively. Conclusion The findings of this meta-analysis confirmed that beta-blocker use in patients with COPD may not only decrease the risk of overall mortality but also reduce the risk of exacerbation of COPD. Beta-blocker prescription for cardiovascular diseases needs to improve in COPD patients.
登录
查看更多内容
影响因子：
9.6
作者：
Andreas, S;Anker, SD;Somers, VK
通讯作者：
Somers, VK
DOI：
10.1016/s0735-1097(01)01225-6
发表时间：
2001-06-01
影响因子：
24
作者：
Chen, J;Radford, MJ;Krumholz, HM
通讯作者：
Krumholz, HM
影响因子：
3.2
作者：
Hanania, Nicola A.;Singh, Supria;Bond, Richard A.
通讯作者：
Bond, Richard A.
影响因子：
3.2
作者：
Lin, Rui;Peng, Hui;Bond, Richard A.
通讯作者：
Bond, Richard A.
影响因子：
5.9
作者：
Au, DH;Bryson, CL;Fihn, SD
通讯作者：
Fihn, SD